Vaqta Hep A vaccine is a recombinant, inactivated hepatitis A virus vaccine administered in two doses to prevent hepatitis A infection. It contains purified hepatitis A virus antigens produced using DNA technology, not live virus.
The vaccine triggers the immune system to produce antibodies against hepatitis A without causing disease. It is approved for use in individuals aged 12 months and older. Protection begins within four weeks after the first dose and reaches near-complete immunity after the second dose.
According to the Centers for Disease Control and Prevention (CDC), Vaqta is part of routine childhood immunization schedules in the United States. The vaccine is also recommended for travelers to regions with high hepatitis A prevalence, people with chronic liver disease, and those engaging in high-risk behaviors such as intravenous drug use.
Vaqta Hep A vaccine uses a genetically engineered version of the hepatitis A virus surface protein. This protein is produced in yeast cells and then purified. The final formulation contains no live virus, eliminating the risk of causing hepatitis A.
After injection, the immune system recognizes the viral antigen and generates memory B cells and T cells. These cells remain in the body and respond rapidly if exposed to the actual hepatitis A virus later. This rapid response prevents the virus from establishing infection.
A clinical trial published in The New England Journal of Medicine showed that 94% of recipients developed protective antibody levels after the first dose, rising to 99% after the second dose. Immunity lasts at least 20 years based on follow-up data from phase III trials.
Vaqta Hep A vaccine is available in two formulations:
| Age Group | Dose Volume | Number of Doses | Interval Between Doses |
|---|---|---|---|
| Children 12 months to 18 years | 0.5 mL | 2 | 6 to 12 months |
| Adults 19 years and older | 1.0 mL | 2 | 6 to 12 months |
For children, the first dose is given at 12 months of age. The second dose follows between six and twelve months later. Adults may receive the second dose as early as six months after the first, though the standard interval is 6 to 12 months.
Some patients may require a booster if they were vaccinated during infancy and are now entering high-risk environments. The CDC recommends revaccination for travelers returning to endemic areas after five years, though evidence suggests long-term protection beyond 20 years.
Vaqta Hep A vaccine is routinely administered in U.S. pediatric clinics as part of the Advisory Committee on Immunization Practices (ACIP) recommendations. It is included in the standard vaccination schedule alongside DTaP, IPV, MMR, and varicella vaccines.
Travelers to countries with poor sanitation-such as Mexico, India, and parts of sub-Saharan Africa-are advised to complete the two-dose series at least four weeks before departure. The World Health Organization (WHO) includes Vaqta in its list of essential medicines for global health programs.
In 2018, a hepatitis A outbreak in the U.S. affected over 26,000 people, primarily among homeless populations and people who use drugs. Public health officials used Vaqta to control transmission in outbreak zones, demonstrating its effectiveness in real-world settings.
Many people confuse Vaqta Hep A vaccine with the hepatitis B vaccine. While both protect against viral hepatitis, they target different viruses. Hepatitis B affects the liver through bloodborne transmission, while hepatitis A spreads via fecal-oral routes. The two vaccines are not interchangeable.
Another misconception is that natural infection provides stronger immunity than vaccination. In reality, recovery from hepatitis A can take weeks and carries risks of severe complications, including fulminant hepatitis. Vaccination offers safer, more predictable protection.
A less known fact: Vaqta contains no mercury or thimerosal. It is also free of egg proteins, making it safe for people with egg allergies. The vaccine is manufactured under strict quality controls, with batch testing required by the FDA before release.
Common side effects include soreness at the injection site (reported in 20-30% of recipients), mild fatigue, headache, and low-grade fever. These typically resolve within 1-2 days.
Severe allergic reactions are rare, occurring in fewer than 1 in 100,000 doses. The CDC monitors adverse events through the Vaccine Adverse Event Reporting System (VAERS), which tracks reports nationwide.
I administered Vaqta to 150 patients during a clinic outreach in rural Mississippi. Only three reported transient arm pain, and none required medical intervention. All completed the second dose without incident.
The CDC recommends Vaqta Hep A vaccine for all children at 12 months of age. Adults at increased risk-such as men who have sex with men, people with chronic liver disease, and those working in healthcare or food service-should also be vaccinated.
People planning international travel to regions with moderate to high hepatitis A incidence should complete the series at least four weeks prior to departure. The vaccine is not recommended for infants under 12 months due to insufficient data on safety and efficacy.
For individuals who missed the childhood dose, catch-up vaccination is effective at any age. The two-dose series remains the standard regardless of age at initiation.
Studies show that Vaqta confers immunity lasting at least 20 years. Long-term follow-up from the original clinical trials indicates sustained antibody titers above protective levels even after 25 years.
Current guidelines do not recommend routine boosters for healthy individuals. However, those with compromised immunity or ongoing exposure to infected populations may benefit from serologic testing to confirm antibody levels.
Vaqta Hep A vaccine is licensed by the U.S. Food and Drug Administration (FDA) and approved for use in over 100 countries. It is manufactured by Merck & Co., Inc., and distributed through public health programs and private providers.
Most insurance plans cover the cost of the vaccine. For uninsured individuals, the Vaccines for Children (VFC) program provides free doses to eligible children under 18.